0000950170-24-005557.txt : 20240118 0000950170-24-005557.hdr.sgml : 20240118 20240118194715 ACCESSION NUMBER: 0000950170-24-005557 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240116 FILED AS OF DATE: 20240118 DATE AS OF CHANGE: 20240118 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Mates Sharon CENTRAL INDEX KEY: 0001585699 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36274 FILM NUMBER: 24543415 MAIL ADDRESS: STREET 1: C/O INTRA-CELLULAR THERAPIES, INC. STREET 2: 3960 BROADWAY CITY: NEW YORK STATE: NY ZIP: 10032 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Intra-Cellular Therapies, Inc. CENTRAL INDEX KEY: 0001567514 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 364742850 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 430 EAST 29TH STREET CITY: NEW YORK STATE: NY ZIP: 10016 BUSINESS PHONE: 212-923-3344 MAIL ADDRESS: STREET 1: 430 EAST 29TH STREET CITY: NEW YORK STATE: NY ZIP: 10016 FORMER COMPANY: FORMER CONFORMED NAME: Oneida Resources Corp. DATE OF NAME CHANGE: 20130122 4 1 ownership.xml 4 X0508 4 2024-01-16 0001567514 Intra-Cellular Therapies, Inc. ITCI 0001585699 Mates Sharon C/O INTRA-CELLULAR THERAPIES, INC. 430 EAST 29TH STREET NEW YORK NY 10016 true true false false Chairman, President & CEO true Common Stock 2024-01-16 4 M false 75361 16.86 A 1125670 D Common Stock 2024-01-16 4 S false 3500 66.38 D 1122170 D Common Stock 2024-01-16 4 S false 65979 67.25 D 1056191 D Common Stock 2024-01-16 4 S false 5882 67.76 D 1050309 D Common Stock 2024-01-17 4 M false 48084 16.86 A 1098393 D Common Stock 2024-01-17 4 S false 30633 66.00 D 1067760 D Common Stock 2024-01-17 4 S false 17451 66.66 D 1050309 D Common Stock 2024-01-18 4 M false 67917 16.86 A 1118226 D Common Stock 2024-01-18 4 S false 67597 65.19 D 1050629 D Common Stock 2024-01-18 4 S false 320 66.25 D 1050309 D Stock Option (right to buy) 16.86 2024-01-16 4 M false 75361 0 D 2024-06-30 Common Stock 75361 124639 D Stock Option (right to buy) 16.86 2024-01-17 4 M false 48084 0 D 2024-06-30 Common Stock 48084 76555 D Stock Option (right to buy) 16.86 2024-01-18 4 M false 67917 0 D 2024-06-30 Common Stock 67917 8638 D This sale was effected pursuant to a Rule 10b5-1 trading plan originally adopted by the reporting person on March 14, 2023 and amended on June 9, 2023. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.685 to $66.68, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.69 to $67.68, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.69 to $67.92, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.36 to $66.3572, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.36 to $67.21, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.84 to $65.82, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.0143 to $66.27, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. This option was granted on June 30, 2014 with an exercise price of $16.86 per share and will expire on June 30, 2024. All shares underlying this option have vested. /s/ Lawrence J. Hineline, Attorney-in-fact 2024-01-18